SAFETY DATA SHEET

Triclabendazole / Abamectin Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Triclabendazole / Abamectin Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 91-105 Harpin Street
         Bendigo  3550, Victoria Australia
Telephone: +1-908-740-4000
Emergency telephone number: 1 800 033 461
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Liver, Blood)

GHS label elements
Hazard pictograms: 
Signal word: Warning
Hazard statements: H373 May cause damage to organs (Liver, Blood) through prolonged or repeated exposure if swallowed.
Precautionary statements: Prevention:
P260 Do not breathe mist or vapours.
Response:
P314 Get medical advice/ attention if you feel unwell.
Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS
SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment: In the event of fire, wear self-contained breathing apparatus.
for firefighters Use personal protective equipment.

Hazchem Code •3Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures
See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation
Use only with adequate ventilation.

Advice on safe handling
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Conditions for safe storage: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triclabendazole</td>
<td>68786-66-3</td>
<td>TWA</td>
<td>30 μg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>Silicon dioxide</td>
<td>7631-86-9</td>
<td>TWA (Respirable dust)</td>
<td>2 mg/m3</td>
<td>AU OEL</td>
</tr>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>TWA</td>
<td>30 μg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection: Chemical-resistant gloves

Remarks: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : 5.0 - 7.0

Melting point/freezing point : < 5 °C

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1,050 - 1,080 g/cm³ (20 °C)

Solubility(ies)
  Water solubility : soluble

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
  Viscosity, kinematic : No data available

Explosive properties : Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Triclabendazole:
Acute oral toxicity: LD50 (Mouse): > 8,000 mg/kg
LD50 (Rabbit): 206 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 0.5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity: LD50 (Rat): > 4,000 mg/kg

Silicon dioxide:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity: LC50 (Rat): > 2.08 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity
Acute dermal toxicity: LD50 (Rabbit): > 5,000 mg/kg

**Abamectin (combination of avermectin B1a and avermectin B1b):**

**Acute oral toxicity:** 
- LD50 (Rat): 24 mg/kg
- LD50 (Mouse): 10 mg/kg
- LDLo (Monkey): 24 mg/kg
- Symptoms: Dilatation of the pupil

**Acute inhalation toxicity:** 
- LC50 (Rat): 0.023 mg/l
- Exposure time: 4 h
- Test atmosphere: dust/mist

**Acute dermal toxicity:** 
- LD50 (Rat): 330 mg/kg
- LD50 (Rabbit): 2,000 mg/kg

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Triclabendazole:**
- Species: Rabbit
- Result: Mild skin irritation

**Silicon dioxide:**
- Species: Rabbit
- Method: OECD Test Guideline 404
- Result: No skin irritation

**Abamectin (combination of avermectin B1a and avermectin B1b):**
- Species: Rabbit
- Result: No skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Triclabendazole:**
- Species: Rabbit
- Result: No eye irritation

**Silicon dioxide:**
- Species: Rabbit
- Result: No eye irritation
- Method: OECD Test Guideline 405
Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Triclabendazole:
Result: Not a skin sensitizer.

Abamectin (combination of avermectin B1a and avermectin B1b):
Test Type: Maximisation Test
Exposure routes: Skin contact
Result: Not a skin sensitizer.

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Triclabendazole:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Silicon dioxide:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Abamectin (combination of avermectin B1a and avermectin B1b):
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Genotoxicity in vivo  
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

Carcinogenicity  
Not classified based on available information.

Components:

Triclabendazole:
Species  : Mouse  
Application Route  : Oral  
Exposure time  : 2 Years  
Result  : negative

Species  : Rat  
Application Route  : Oral  
Exposure time  : 2 Years  
Result  : negative

Silicon dioxide:
Species  : Rat  
Application Route  : Ingestion  
Exposure time  : 103 weeks  
Result  : negative

Abamectin (combination of avermectin B1a and avermectin B1b):
Species  : Rat  
Application Route  : Oral  
Exposure time  : 105 weeks  
Result  : negative

Species  : Mouse  
Application Route  : Oral  
Exposure time  : 93 weeks  
Result  : negative

Reproductive toxicity  
Not classified based on available information.

Components:

Triclabendazole:
Effects on fertility  : Test Type: Fertility/early embryonic development  
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 5.5 mg/kg body weight

Effects on foetal development:

Silicon dioxide:
Effects on foetal development:

Abamectin (combination of avermectin B1a and avermectin B1b):
Effects on fertility:

Remarks:
Maternal toxicity observed.

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 10 mg/kg body weight
Result: Effects on foetal development
Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 3 mg/kg body weight
Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 50 mg/kg body weight

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 200 mg/kg body weight
Result: Effects on foetal development
Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 5.5 mg/kg body weight

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.12 mg/kg body weight

Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
Result: Fetotoxicity

Effects on foetal development:
- Test Type: Embryo-foetal development
- Species: Mouse
- Application Route: Oral
- General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
- Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
- Result: Cleft palate
- Remarks: Adverse developmental effects were observed

- Test Type: Embryo-foetal development
- Species: Rabbit
- Application Route: Oral
- Developmental Toxicity: LOAEL: 2 mg/kg body weight
- Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
- Remarks: Adverse developmental effects were observed

- Test Type: Development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
- Result: Teratogenic effects

Reproductive toxicity - Assessment:
- Some evidence of adverse effects on sexual function and fertility, based on animal experiments.
- Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
May cause damage to organs (Liver, Blood) through prolonged or repeated exposure if swallowed.

**Components:**

**Triclabendazole:**
- Target Organs: Liver, Blood
- Assessment: May cause damage to organs through prolonged or repeated exposure.

**Abamectin (combination of avermectin B1a and avermectin B1b):**
- Exposure routes: Ingestion
- Target Organs: Central nervous system
- Assessment: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Triclabendazole:**
### Triclabendazole / Abamectin Formulation

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>6.6 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>69 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Blood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>3.4 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>37 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver, Blood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>29 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>4 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver</td>
</tr>
</tbody>
</table>

**Remarks:** No significant adverse effects were reported

### Silicon dioxide:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1.3 mg/m3</td>
</tr>
<tr>
<td>Application Route</td>
<td>Inhalation (dust/mist/fume)</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
</tbody>
</table>

### Abamectin (combination of avermectin B1a and avermectin B1b):

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, ataxia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>4.0 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, ataxia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>0.25 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>0.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, weight loss</td>
</tr>
</tbody>
</table>
Remarks: mortality observed

Species: Monkey
NOAEL: 1.0 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Triclabendazole:
Ingestion: Symptoms: Abdominal pain, Sweating, Headache, Nausea, Vomiting, anorexia, Dizziness, Fatigue, Cough, Fever, pruritis

Abamectin (combination of avermectin B1a and avermectin B1b):
Ingestion: Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Silicon dioxide:
Toxicity to fish: LC50 (Danio rerio (zebra fish)): > 10,000 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 24 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Desmodesmus subspicatus (green algae)): > 10,000 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

NOEC (Desmodesmus subspicatus (green algae)): 10,000 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Abamectin (combination of avermectin B1a and avermectin B1b):
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
Exposure time: 96 h
SAFETY DATA SHEET

Triclabendazole / Abamectin Formulation

Version 1.2
Revision Date: 10.12.2020
SDS Number: 5341816-00003
Date of last issue: 09.10.2020
Date of first issue: 05.12.2019

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l
Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Americamysis): 0.022 µg/l
Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0.34 µg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l
Exposure time: 32 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 0.03 µg/l
Exposure time: 21 d

NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l
Exposure time: 28 d

Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Persistence and degradability

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Stability in water: Hydrolysis: 50 % (< 12 h)

Bioaccumulative potential

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Bioaccumulation: Bioconcentration factor (BCF): 52
Partition coefficient: n-octanol/water: log Pow: 4
Mobility in soil

**Components:**

**Abamectin (combination of avermectin B1a and avermectin B1b):**
Distribution among environmental compartments: log Koc: > 3.6

**Other adverse effects**
No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods**

- **Waste from residues:** Dispose of in accordance with local regulations.
- **Contaminated packaging:** Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION**

**International Regulations**

**UNRTDG**
- **UN number:** UN 3082
- **Proper shipping name:** ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
- **Class:** 9
- **Packing group:** III
- **Labels:** 9

**IATA-DGR**
- **UN/ID No.:** UN 3082
- **Proper shipping name:** Environmentally hazardous substance, liquid, n.o.s. (Abamectin (combination of avermectin B1a and avermectin B1b))
- **Class:** 9
- **Packing group:** III
- **Labels:** Miscellaneous
- **Packing instruction (cargo aircraft):** 964
- **Packing instruction (passenger aircraft):** 964
- **Environmentally hazardous:** yes

**IMDG-Code**
- **UN number:** UN 3082
- **Proper shipping name:** ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
- **Class:** 9
- **Packing group:** III
- **Labels:** 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

ADG
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Abamectin (combination of avermectin B1a and avermectin B1b))
Class : 9
Packing group : III
Labels : 9
Hazchem Code : •3Z

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information
Revision Date : 10.12.2020
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN